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Abstract 
Randomized controlled trials (RCTs) generally provide the most reliable evidence.  When participants in RCTs are selected with 
respect to characteristics that are potential treatment effect modifiers, the average treatment effect from the trials may not be 
applicable to a specific target population.  We present a new method to project the treatment effect from a RCT to a target group that 
is inadequately represented in the trial when there is heterogeneity in the treatment effect (HTE).  The method integrates RCT and 
observational data through cross-design synthesis.  An essential component is to identify HTE and a calibration factor for 
unmeasured confounding for the observational study relative to the RCT.  The estimate of treatment effect adjusted for unmeasured 
confounding is projected onto the target sample using G-computation with standardization weights.  We call the method Calibrated 
Risk-Adjusted Modeling (CRAM) and apply it to estimate the effect of angiotensin converting enzyme inhibition to prevent heart 
failure hospitalization or death.  External validation shows that when there is adequate overlap between the RCT and the target 
sample, risk-based standardization is less biased than CRAM.  However, when there is poor overlap between the trial and the target 
sample, CRAM provides superior estimates of treatment effect. 
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1. Introduction 
Mainly due to a lack of external validity, some medical guideline-makers and policy-makers believe that the evidence base from 
human trials is inadequate, i.e. that trials provide insufficient evidence to guide care for key target populations.1, 2  In recent years 
many have called for trials that are less exclusionary and more pragmatic.3, 4  Selection by trials is not entirely avoidable, as is 
demonstrated by informed consent.  Therefore, limited external validity is inherent to a trial design.   
 
Together with a companion article that details statistical methodology and simulations, this report presents a novel method to project 
the treatment effect from a trial to a target group that is poorly represented in the trial, thus extending the applicability of trial 
evidence.  Here we present a clinical application and external validation.  The method does this by using individual-level data from a 
trial and observational data where the observational data has a broader distribution of effect modifiers such that it partially overlaps 
the trial sample and the target sample.  Then the treatment effect from the trial can be projected to the target sample.  The essential 
component of the method is to identify a calibration factor for unmeasured confounding for the observational study relative to the trial.  
The calibration factor makes it possible to estimate a treatment effect in the observational data with adjustment for unmeasured 
confounding.     
 
Heart failure (HF) is the clinical example for demonstrating the proposed methods. HF prevalence is approximately 7.9% among 
Medicare beneficiaries and 12.0% among those dually enrolled in Medicare and Medicaid.5  Despite this importance to policy and 
providers, fundamental questions remain about use of one of the most important treatments, angiotensin converting enzyme 
inhibition (ACEi).  A major guideline concisely stated the problem with respect to the effectiveness of ACEi:6 “…primarily men are 
enrolled in clinical trials of treatments for HF; however, the majority of patients with HF in the general population are women… [and] 
most large, multicenter trials have not included sufficient numbers of women to allow conclusions about the efficacy and safety of 
their treatment... Some research has suggested that women with HF, particularly with asymptomatic reduced left ventricular ejection 
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fractions, may not show survival benefits from ACE inhibition.”  A previous attempt to address the question of efficacy of ACEi in 
women used aggregate data meta-analysis7 and concluded that “women with asymptomatic [left ventricular] systolic dysfunction may 
not achieve a mortality benefit when treated with ACE inhibitors.”  There is evidence that the distribution of characteristics such as 
gender and old age is different in the target population than in the evidence base.  For example, women above age 75 make up 51% 
of people with HF in Medicare and 35% in Medicaid (Data are our calculations using National Health and Nutrition Examination 
Survey, 1999-2004) but the proportion of women above age 75 in trials is lower as the cited guidelines states and we will show.  The 
objectives of the clinical application study were to demonstrate the utility of CRAM for estimating treatment effect in a target sample 
and to externally validate CRAM results. 
 
2. Data Sources and Participants 
Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry   
The SOLVD trials were designed to understand whether the ACEi enalapril reduced mortality in people with a low left ventricular 
ejection fraction (≤0.35).8  Designed as a pair, the treatment trial (SOLVD-T, n=2,569) recruited patients with an overt history of HF 
and the prevention trial (SOLVD-P, n=4,228) did not.  The trial reported estimated a treatment benefit for the primary outcome of 
death in SOLVD-T (SOLVD-T relative risk 0.86, P-value 0.0036; SOLVD-P 0.92, P-value 0.30) and benefit for the secondary 
outcome of death or HF hospitalization in both trials (SOLVD-T relative risk 0.74, P-value 0.0001; SOLVD-P 0.80, P-value <0.001).9, 
10  A related registry (SOLVD-R, n=5,100 not also in a SOLVD trial) was created to understand the natural history of patients with a 
low left ventricular ejection fraction (≤0.35) or an overt history of HF.11  We use the SOLVD-T trial as the source of evidence, SOLVD-
R registry as the bridge sample and the SOLVD-P as a target sample.  In practice a trial would not be chosen as the target sample 
but we did so in order to have the ability to provide external validation of the treatment effect projected to it, as further explained 
below. 
 
There was evidence of strong selection into the trials as samples were 6.4% and 7.4% of people screened and eligible for SOLVD-T 
and SOLVD-P, respectively.9  The total number of people screened and eligible was not known for SOLVD-R.  However, the number 
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of exclusion criteria was 26 for the trials and only 5 for the registry.  We reviewed reported SOLVD inclusion and exclusion criteria 
one at a time (Appendix Table 1).   
 
The main outcome chosen for this study was HF hospitalization or death at 1 year, an outcome that was pre-specified by trial 
designers.  The combined outcome provided more power to examine HTE and was valid because the direction of treatment effect 
was the same for each component outcome.12  The time horizon of 1 year created synchronization across the trials and registry.  
Details concerning measurement for the outcome and predictors, which are listed in Table 1, are published.8-11 
 
3.  Testing for heterogeneity of treatment effect in the trial  
When the treatment effect is heterogeneous, the average treatment effect from the trials is neither generalizable to the larger at-risk 
population nor applicable to a specific target sample.  Therefore, ascertaining whether HTE is present is an essential aspect of our 
methodology.  Various patient characteristics can modify the effect of the treatment.  We follow a large literature demonstrating that 
baseline risk of the outcome is often a potent treatment effect modifier on the relative risk scale,13-20  However, any variable found to 
be a strong treatment effect modifier could be used in place of baseline risk for the proposed method.  We collected external 
evidence regarding which patient characteristics predict the outcome by performing a literature search and asking local experts to 
identify validated equations.  In this way we identified 37 externally-validated predictors (Appendix Tables 2 and 3).21-27  For each 
predictor we examined study datasets to identify corresponding data (Appendix Table 4).  In some cases we employed clinical 
judgment regarding equivalence.  E.g., serum hematocrit/3 was used when serum hemoglobin concentration was not available.  
Having established which predictors were present in at least one study, we examined the proportion of missing data.  We use 
predictors with ≥85% non-missing values during risk modeling (Appendix Table 5).   
 
To obtain baseline risk estimates we entered treatment and other predictors into a Cox proportional hazards model.28  There was a 
separate model for the trial and bridge sample, which was then applied to the target sample.  This was done to imitate practice 
settings where outcomes data for the target sample may not be available.  The cumulative baseline hazard at 1 year and the linear 
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predictor from the model enabled calculation of individual baseline risk at 1 year.29  Plots of risk calibration provided an assessment 
of the validity of individual risk estimates.  Specifically, we made risk quintile groups with predicted risk, calculated the observed risk 
for each quintile with the Kaplan-Meier survival function30 and then plotted the geometric mean of observed risk versus predicted risk 
for each quintile (Appendix Figure 1).    
 
We also use the Follmann test, which tests for HTE in one step.31  The Follmann test provides a likelihood ratio test statistic for H0: β0 
= β1 versus HA: α β0 = β1, α1, where β is the regression coefficients for an underlying vector of covariates that identifies HTE.  α<1 is 
a negative interaction, α>1 is a positive interaction and α=1 is the null hypothesis.  This initial step to identify HTE is done on the 
pooled trial and bridge samples. In this example using survival analysis, baseline hazard is allowed to vary between the two sample 
strata.   
 
4. Standardization of treatment effect from trial to target sample 
Two standardization approaches are compared because simulation studies have shown that neither approach is uniformly better 
than the other in terms of bias (see companion paper).   
 
4.1 Covariate-based standardization 
A logistic regression model for predicting study membership (S=1 denotes membership in the bridge sample and S=0 denotes 
membership in trial) on the basis of covariates is fitted using a boosted approach.  The covariates chosen were personal 
characteristics known to be associated with the outcome (e.g. age, gender, chronic disease status).  For each individual in the trial, 
the probability of being in the bridge sample, p1 = prob(S=1), is estimated.  Each person in the trial is weighted with the odds of being 
in the bridge sample, which is p1/(1-p1).  Treatment effect was estimated using a weighted proportional hazard model with treatment 
indicator as the only covariate.  A robust standard error is computed using a sandwich estimator.32  When the Follmann test is 
significant, simulation studies show that the next approach with risk-based standardization is less biased (see companion paper). 
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4.2 Risk-based standardization 
Risk-based standardization is better than covariate-based standardization when baseline risk is an effect modifier and the Follmann 
test of interaction is significant.  This approach is like covariate based standardization except that instead of covariates study 
membership is predicted as a function of 1-year risk of outcome.  In addition a flexible logistic regression model with a spline function 
was used to model the baseline risk variable, fitted using the generalized additive model approach.33  
 
5. Calibrated, Risk-Adjusted Modeling 
For a brief conceptual overview of CRAM, please see section 2 of a companion paper.  The CRAM approach utilizes a bridging 
sample to provide an evidentiary link between the evidence source and target sample. 
 
5.1 The causal estimand 
The goal is to estimate the effect of treatment where A = 1 for enalapril treatment and A=0 for control, on the failure time T, which is 
subject to right censoring.  Let Ta denote the potential failure time when A=a (where a=0, 1).  Here the causal parameter of interest is 
the marginal log-hazard ratio, defined as: 
 
t = log[-log(prob(T1 > t)] – log[-log(prob(T0 > t)] ,      (1) 
 
The models for the hazard rate of failure time, (t), which is defined as: prob (t < T ≤ t+dt | T ≥ t) dt, where dt is a small increment of 
time.  The Cox proportional hazards model is used throughout to estimate the marginal log-hazard ratio.  In the trial sample, this is 
the standard intent-to-treat effect (without any covariate adjustment).  In the observational bridge sample, t is computed using the 
G-computation formula given in Stitelman et al.34  This is a causal estimate of treatment effect under the usual assumptions of 
consistency, no unmeasured confounding and correct model specification for the hazard rate.35  The intent-to-treat effect is 
estimated, so there is the assumption that non-compliance in the trial is negligible.  
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[Table 1 about here] 
A comparison of the proposed novel modeling approach to inverse probability of treatment weighted and standardization is presented 
in Table 1.  Major differences among modeling approaches are shown, including the major focus on HTE and unmeasured 
confounding provided only by CRAM.  Standardization approaches are partially cross-design synthetic approaches in the sense that 
they use information from both the trial and bridge sample.  However, they are only partially synthetic because they do not use the 
treatment status and outcome data from the bridge sample.  Furthermore they do not focus on HTE.  CRAM employs full cross-
design synthesis because it uses information about the treatment status and outcome from the bridging study to examine HTE as 
well as unmeasured confounding. 
 
5.2 Accounting for heterogeneity of treatment effect and unmeasured confounding in the bridge sample 
The next step is to account for unmeasured confounding by finding the parameter that optimally matches the bridge sample’s 
treatment effect to the trial treatment effect.  This is the CRAM calibration step.  It can be shown that an unmeasured confounder can 
be captured by a single variable that when incorporated, for example in model (2), will provide an unbiased estimate for the marginal 
treatment effect formula (1).   A survival (proportional hazards) model for the outcome that depends on treatment A (= 0,1) and 
underlying baseline risk R (1-year risk of outcome) was used.  Since there is uncertainty about the correct model for the potential 
outcome, Ta, two models are used:  
 
(t) = 0(t) . exp(A A + RR + AR A*R + UU)      (4) 
(t) = 0(t) . exp(A A + RR + AR A*R + UU + AU A*U)     (5) 
where 0(t) is the baseline hazard for the outcome.  Model (4) allows two-way interactions of treatment A only with baseline risk, and the 
unmeasured confounder U enters only as a first-order term.  The unmeasured confounder U is modeled as described in the 
companion paper.  Model (5) allows two-way interactions of treatment A with baseline risk as well as with unmeasured confounder U.   
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CRAM estimates that use information from the bridge sample are compared to estimates derived by standardizing the trial sample to 
the target sample.  The standardization methods are the same as used to standardize the trial sample to the bridge sample, as 
discussed in section 4.  Covariate based or risk based standardization can be used, depending on the results of the test for 
interaction or Follmann test, as discussed in section 3. 
 
To compare CRAM to standardization estimates of treatment effect when there is little overlap between the trial and target sample, 
we repeated the projection procedures described above for a more “distant” target sample.  This was comprised by the lowest 3 
quartiles of risk in the target sample, i.e. those with the least overlap with the trial sample.  We also examined the conventional target 
sample suggested by the clinical literature: women older than 75 years. 
 
6. External Validation 
We compare the projected log hazard ratios to the actual treatment effect in the clinically appropriate target sample, which our case 
happens to be the SOLVD-P trial so that the CRAM method’s treatment effect can be externally validated.  An additional strength of 
our example is that the evidence and target sample were designed together so data collection was coordinated and data 
measurement discrepancies were absent.  We compute two treatment effects in the target sample.  The first is the treatment effect 
that is unadjusted for any prognostic variables: 
 
(t) = 0(t) . exp(A A)        (6) 
The second is the marginal treatment effect obtained by applying the G-computation formula to the following model that conditions on 
baseline risk: 
 
(t) = 0(t) . exp(A A + RR)       (7) 
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7. Results 
[Table 2 about here] 
By comparing patient characteristics one at a time (Table 2) we found that the SOLVD trials compared to the SOLVD-R had a lower 
proportion women compared to the observational studies (11.3-19.6% vs. 28.8-42.8%), and a markedly lower proportion of older 
women (0.6-1.4% vs. 8-20.8%).  However, the trials had a much higher proportion history of myocardial infarction and Instrumental 
Activities of Daily living disability compared to the observational studies, and a higher proportion of former or current smoking, history 
of diabetes mellitus and fair or poor general health.  The trials had a lower proportion of history of atrial fibrillation, history of chronic 
obstructive pulmonary disease or hospitalization in the last year and on average a lower systolic blood pressure.  In both trials, the 
unadjusted treatment effect favored treatment however in the target sample the treatment effect was qualitatively different and 
suggested treatment harm. Of course, the unadjusted treatment effect in the target sample is expected to be confounded by 
treatment selection. 
 
7.1. Identification of heterogeneity of treatment effect in the trial   
The likelihood ratio test of HTE according the baseline risk in the trial was significant with the Cox proportional hazards model (P-
value = 0.0013).  The Follmann parameter was 0.68.  A result <1 implies that as baseline risk increases the treatment effect 
expressed as a log hazard ratio becomes more negative, i.e. there is stronger risk reduction.  Similar to the likelihood ratio test using 
the Cox model, the Follmann test for HTE according to a linear combination of covariates yielded a highly significant result (LRT 
statistic = 12.9, P-value = 0.00033).   
 
7.2. Distributions of treatment effect modifier in the different samples 
[Figure 1 about here] 
Visual comparison of risk distributions showed that the SOLVD-T trial had the highest distribution of 1-yr risk of HF hospitalization or 
death.  This distribution was shared partially with the distributions in the SOLVD-R bridge sample and SOLVD-P target sample 
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(Figure 1).  In other words, the bridge sample and to a greater degree the target sample were selected to be not as high risk as the 
trial.  Combined with the information from the Follmann test above, this meant that less strong treatment effect i.e. less risk reduction 
would be expected in SOLVD-R and SOLVD-P compared to SOLVD-T.   
 
[Table 3 about here] 
7.3 Calibration - Accounting for unmeasured confounding in the bridge sample 
An unmeasured confounder U that decreases the probability of taking treatment, but increases the mean failure time (i.e. increasing 
levels of confounder decreases the failure rate), would account for the discrepancy between bridge sample and standardized 
treatment effects noted in Table 2.  Conversely, a U that increases the probability of taking treatment, but decreases the mean failure 
time (i.e. increasing levels of confounder increases the failure rate), would have the same effect.  Therefore, it was sufficient to 
consider only one direction.  1 < 0 and 0 < <1 were considered.  To examine the sensitivity of results to U, CRAM was performed 
for two different values of 1, -0.5 and -1.0.  For model (4) with 1 -0.5 and -1.0, respectively, the optimal * were 0.70 and 0.49.  For 
model (5) with 1 -0.5 and -1.0, respectively, the optimal * were 0.72 and 0.56.  As expected for both models, when the effect of the 
unmeasured confounder on treatment selection was stronger (1 had a larger absolute value), the effect of the unmeasured 
confounder on failure time needed to calibrate to the same treatment effect was smaller (* was weaker).  In addition, when the 
confounded treatment effect was larger than the trial treatment effect (to the right on a log scale or further from the null on a hazard 
ratio scale), 1 and * have different signs.   
 
 [Tables 4 and 5 about here] 
7.4 Standardization and CRAM results 
As shown in Table 1, if the treatment effect from the evidence source were assumed to apply to the target sample, ignoring sample 
selection and HTE, the true treatment effect (using Eq. 1) was a log hazard ratio of -0.51 (standard error=0.08).  Covariate-based 
standardization of the trial to the target sample estimated the treatment effect as a log hazard ratio of -0.50 (standard error=0.22; Z-
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test statistic 2.27) and risk-based standardization of the trial to the target sample estimated the treatment effect as a log hazard ratio 
of -0.31 (standard error=0.13; Z-test statistic=2.38).  Using CRAM the projected treatment effect was -0.45 or -0.43 (standard 
error=0.13 or 0.16, respectively) using models (4) and (5), as shown in Table 3.  The standard errors demonstrated that covariate-
based standardization and CRAM were more efficient than risk-based standardization.   
 
To compare CRAM to standardization estimates of treatment effect when there is little overlap between the trial and target sample, 
we also repeated the projection procedures described above for modifier distant target sample, as shown in Table 4.  The true 
treatment effect in this sample (using Eq. 1) was -0.35 (standard error=0.19).  Covariate-based standardization estimated the 
treatment effect as a log hazard ratio of -0.55 (standard error=0.43) and risk-based standardization of the trial to the distant target 
sample estimated the treatment effect as a log hazard ratio of -0.11 (standard error=0.19; Z-test statistic=0.59).  The projected 
treatment effect using CRAM was closest at -0.28 to -0.33 (standard error=0.18 to 0.21). 
 
Finally we compared CRAM to standardization estimates of treatment effect to the predefined conventional target sample of women 
older than 75 years, as shown in Table 5.  Risk-based standardization of the trial to women older than 75 years estimated the 
treatment effect as a log hazard ratio of -0.64 (standard error=0.13; Z-test statistic=5.06).  For the conventional target sample the 
projected treatment effect using CRAM was -0.41 to -0.44 (standard error=0.08 to 0.09). 
 
7.5 External validation of CRAM results 
By using a randomized trial as the target sample in this methodology study, we are able to provide externally valid treatment effect 
estimates.  In the target sample, the treatment effect was log hazard ratio -0.28 (SE 0.10, P-Value = 0.006). As can be shown by 
comparing results to Table 3, risk-based standardization performed superiorly to covariate-based standardization and CRAM.  In the 
distant target sample, the treatment effect was log hazard ratio -0.37 (SE 0.16, P-Value = 0.023).  As can be shown by comparing 
results to Table 4, estimates from CRAM, using models that incorporate risk-based heterogeneity, performed superiorly to either 
standardization approach.  We could not estimate the treatment for women older than 75 years in the validation trial SOLVD-P due to 
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small sample size. Therefore, it was not possible to externally validate CRAM or standardization results for women older than 75 
years. 
 
8. Discussion 
This report presents a novel method to project the estimation of a treatment effect from a trial or trials to people who were not in the 
trial using observational data.  In order to draw on strengths and address limitations that are inherent to each design, the method 
uses individual-level data from a synthetic study design dyad with a trial and observational studies.  Attention to HTE and a 
calibration factor for unmeasured confounding for the observational study relative to the trial make it possible to estimate a treatment 
effect in the observational data.  In this way the method uses empirical data to inform a sensitivity analysis for unmeasured 
confounding of treatment effects for people not in the trial.  The proposed methods will facilitate the synthesis of evidence base 
provided by trials, under appropriate conditions, with evidence from target populations not included by trials.  The methods can be 
used for a trial and registry or a trial and a cohort study.   
 
CRAM differs from standard meta-analysis, which typically combines the results of several studies with similar design, in two 
important ways: it integrates studies with different designs and it uses individual-level data to understand and account for HTE and 
biases.  The ability of CRAM to remove unmeasured confounding from the registry data in the bridge sample and provide a sensible 
estimate of treatment effects in the target sample is promising.  Importantly, this report found a qualitative discrepancy between the 
treatment effect estimated for the target sample using only observational data and the treatment effect estimated with CRAM.  Using 
only observational data with adjustment for treatment selection according to measured factors, treatment was estimated to increase 
risk of the primary outcome; using CRAM or the standardization approach, treatment was estimated to decrease the risk. The 
approach we compared to CRAM, inverse probability treatment weighting, estimates treatment effect using only the target sample.  
This approach might yield unbiased marginal treatment effects only when there is no unmeasured confounding.  Standardization is 
more like cross-design synthesis approaches in the sense that it uses information from both the trial and bridge sample.  However, 
standardization is only partially synthetic it does not use the treatment status and outcome data from the bridge sample.  Furthermore 
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standardization approaches do not explicitly examine HTE.  CRAM uses information about the treatment status and outcome from 
the bridging study and examines both HTE and unmeasured confounding.   
 
Inverse probability of treatment weighted (IPTW) would commonly be used to model treatment effect in observational data.  An 
approach based on IPTW does not require a model for the outcome - just information on the outcome - which is a desirable feature 
since a large number of covariates and a powerful machine learning approach can be used not only to predict treatment selection but 
also to optimize covariate balance.   However, IPTW does not focus on HTE and does not leverage information from the target 
sample.  In our example, IPTW is not a relevant comparator because we use a randomized treatment trial as our target sample in 
order to make external validation possible.   
 
The findings of our external validation were that when there is substantial overlap between the trial and the target sample, 
standardization approach was better than CRAM, i.e. it was less biased than CRAM.  However, when there is poor overlap between 
the trial and the target sample, CRAM was superior to standardization and provided valid estimates of treatment effect.  Why did 
CRAM perform superiorly to standardization when the target sample was distant from the trial sample?  This is likely due to 2 
reasons: first, a greater overlap between the bridge sample used by CRAM and the distant target sample, and second, trial 
standardization is not outcome model based, whereas CRAM projection is based on outcome model that incorporates HTE.  
Consequently the models which incorporate risk-based effect heterogeneity might be expected to do better when there is indeed 
heterogeneity due to baseline risk.  A vast majority of the standardization weights from the trial to the distant target sample are 0, 
whereas there is a smaller proportion of zero weights when standardizing the bridge sample to the distant target sample: 
approximately 60% for the trial sample versus 40% for the bridge sample (Figure 2).  Further, the larger non-zero weights for trial 
sample are larger than those of the bridge sample.  This results in standardization estimates being more unstable than the CRAM 
estimate that uses the bridge sample to calibrate. 
[Figure 2 about here] 
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This report also illustrates how evidence regarding older women appeared lacking in the studied trial.  There were too few older 
women in the trials to analyze as a subgroup (Table 1).  However, trial participants may be different from a target group in many 
ways, not just according to age group and gender.  We also found that there was varying direction to the correlations between a 
patient characteristic and being in the trial (e.g., some co-morbid diseases were positively correlated with being in the trial, others 
negatively).  We visually examined the distribution of women older than 75 and found that they were actually distributed across the 
range of baseline risk shown in Figure 1.  These findings suggest that general rules regarding selection into trials (such as the idea 
that trials exclude older, sicker people) should be viewed with skepticism and labels such as “older women” are not very informative.  
Even though SOLVD-T included few older women, its results may still apply many older women to the extent that exchangeability 
needs to be judged according to many characteristics, not just age and gender. 
 
There are several clinical implications of the CRAM results.  We found HTE in the trial, which makes a formal assessment of 
applicability of varying treatment effects essential.  HTE according to baseline risk of outcome in SOLVD-T has not been reported 
previously to our knowledge.  The original trial report conducted 4 pre-specified subgroup analyses, based on tertiles: serum sodium 
concentration, ejection fraction and etiology of heart failure.  In addition to the pre-specified analyses, due to interim information a 
subgroup analysis was conducted according to 4 levels of New York Heart Association classification.  There was a suggestion of 
interaction by ejection fraction such that the tertile with the highest ejection fraction did not benefit (interaction P-value = 0.03).9  We 
report highly significant HTE according to baseline risk such that people at lower risk received smaller treatment benefit.  This finding 
is consistent with prior research showing that multivariate risk scores have greater power than univariate variables to identify HTE.36   
While standardization was useful for estimating the treatment effect for people at somewhat lower risk of the outcome, such 
representing the overall SOLVD-P sample, CRAM performed better for people at lower risk such as those representing a distant 
target sample.  In the case of HF, as with other conditions,37 people at low risk comprise the majority of people not enrolled in a trial. 
 
The CRAM method makes assumptions and has requirements that should be examined carefully.  CRAM assumes that the settings 
for unmeasured confounding obtained in the bridge sample are also applicable to the target sample. This is not too unrealistic.  It is 
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also sensible, if CRAM is viewed as an analytic device that uses trial data to narrow the otherwise wide scope of sensitivity analyses 
for unmeasured confounding in observational data.  For projecting a treatment effect for the target sample, CRAM assumes that the 
same outcome model that is used in the bridge sample also holds in the target sample.  The approach here assumed a non-time-
varying intervention and did not deal with different patterns of adherence to treatment.  CRAM relies on individual-level data for 
important patient characteristics.  While the requirement of individual level data from trials and observational studies limits feasibility 
across scenarios, we believe that individual-level data is essential to validly account for HTE and treatment selection bias.  A real 
limitation is that the method accounts for heterogeneity due to patient-related characteristics, but not for design-related features. This 
is because design-related features that contribute to HTE can vary from one study to another, and consequently it is much more 
challenging to develop a general methodology to account for all of them.   
 
In order to perform CRAM it is necessary to have sufficient overlap between a trial and observational study to perform calibration.  
This will not always be available.  Furthermore, when there is overlap the observational study must have sufficient people exposed 
and unexposed to treatment in the bridge sample.  An important assumption is that a proper metric for exchangeability and 
calibration was used.   CRAM assumes that important measurement discrepancies between studies have been addressed and that 
missing data is ignorable.  Fortunately, the plausibility of each of these assumptions can be assessed 
 
In summary, CRAM integrates studies with different designs and uses individual-level data to rigorously understand and account for 
heterogeneity of treatment effects and biases in observational (bridging) data in order to apply treatment effects from a trial to people 
not adequately represented in the trial.  External validation showed that when there is adequate overlap between the trial and the 
target samples, risk-based standardization was less biased than CRAM.  However, when there is poor overlap between the trial and 
the target samples, CRAM provided superior estimates of treatment effect. 
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TABLES AND FIGURES. 
Table 1. Modeling the Treatment Effect of Enalapril on Mortality or Heart Failure Hospitalization – A Comparison of Approaches. 
 
Standardization, 
Covariate-baseda 
Standardization,  
Risk-based 
CRAM, U-adjusteda CRAM, U Interaction-
adjusteda 
 
Samples Used Trial, Target (but does 
not use information on 
treatment status and 
outcome from the 
bridging sample) 
Trial, Target (but does 
not use information on 
treatment status and 
outcome from the 
bridging sample) 
Cross-design synthesis: 
Trial, Bridge, Target 
Cross-design synthesis: 
Trial, Bridge, Target 
Heterogeneity 
of Treatment 
Effect 
Addressed indirectly Addressed indirectly Major focus Major focus 
Unmeasured 
Confounding 
Not a concern Not a concern Major focus. Assumes 
unmeasured confounding 
transportable from bridge 
to target sample. 
Major focus, including the 
possibility of interaction 
with an unmeasured 
confounder.  Assumes 
unmeasured confounding 
transportable from bridge 
to target sample. 
Overlap Unstable when there is 
little overlap between 
samples. 
Unstable when there is 
little overlap between 
samples. 
Uses observational study 
sample as bridge to 
address little overlap 
between trial and target 
samples. 
Uses observational study 
sample as bridge to 
address little overlap 
between trial and target 
samples. 
Outcome data Not required Not required Required in trial and 
bridge samples but not in 
the target sample. 
Required in trial and 
bridge samples but not in 
the target sample. 
Outcome 
model 
Not required Not required Required Required 
Cross-design 
synthesis 
Partial Partial Full Full 
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Other 
Comments 
Does not require a model 
for the outcome – need 
sufficient information from 
the target sample. 
Assumes given 
covariates there is no 
additional confounding.   
Does not require a model 
for the outcome – need 
sufficient information from 
the target sample. 
Assumes given baseline 
risk there is no additional 
confounding.  
Need outcome in trial and 
bridge samples but not in 
the target sample. 
 
 
a U stands for unmeasured confounding 
Other footnotes: All models use the Cox proportional hazards model.   
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Table 2. Overall Participant Characteristics and Unadjusted Treatment Effects According to Study. 
Sample Evidence Source Bridge Target  
Study SOLVD Treatment 
Trial 
(n=  2,569) 
SOLVD Registry 
(n= 5,100) 
SOLVD Prevention 
Trial 
(n=  4,228) 
Study Type RCT Observational RCTa 
Proportion    
Female 19.6 28.8 11.3 
Age ≥75 years 5.8 16.1   4.2 
Female and age ≥75 years   1.4   8.0 0.6 
Smoking status    
Never 23.2 29.1 20.8 
Former 54.7 48.0 55.6 
Current 22.1 22.9 23.6 
History of diabetes mellitus 25.8 24.6 15.3 
History of myocardial infarction 65.8 76.0 80.1 
History of atrial fibrillation 10.8 15.1 4.3 
Dependent edema 16.8 29.0 4.4 
Pulmonary edema 25.7 40.6 7.5 
Lung crackles 12.1 36.3 2.6 
Diuretic use 85.5 8.0 16.7 
History of chronic obstructive 
pulmonary disease 10.0 17.7 5.4 
History of stroke 7.7 8.9 5.9 
General Health    
Excellent 2.3  5.2 
Very good 10.2  19.2 
Good 31.0  37.7 
Fair 41.9  31.6 
Poor 14.7  6.3 
Difficulty in any Instrumental 
Activities of Daily Living 52.6  33.3 
Hospitalization within last year 43.4 82.4 41.3 
Angiotensin converting enzyme    
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inhibitor exposure 
Any ACEi n/a 37.9 n/a 
Enalapril 50.0 n/a 49.9 
    
Mean / (standard deviation)    
Age, years 60.4 62.8 58.7 
 (9.9) (12.2) (10.3) 
Left ventricular ejection fraction, % 24.9 31.9 28.3 
 (6.7) (9.7) (5.6) 
Cardiothoracic ratio 0.6 0.7 0.5 
 (0.5) (0.5) (0.5) 
Systolic blood pressure, mmHg 124.9 128.2 125.4 
 (17.5) (22.0) (16.4) 
Diastolic blood pressure, mmHg 76.8 77.0 78.0 
 (10.2) (13.0) (9.6) 
Resting pulse, beats per minute 79.9 82.1 74.9 
 (13.2) (17.2) (12.4) 
Serum creatinine, mg/dL 1.3 1.3 1.2 
 (0.4) (0.5) (0.3) 
Serum sodium, meq/dL 139.7 138.1 140.2 
 (3.2) (4.2) (2.9) 
Serum hemoglobin, g/dL 14.1  14.3 
 (1.6)  (1.4) 
Body weight, kg 79.7 78.2 81.2 
 (16.6) (17.7) (14.3) 
Unadjusted treatment effect, log 
hazard ratio (SE, P-value) 
-0.51 (0.080, 
<0.0001) 
0.47 (0.05, <0.0001) -0.28 (0.10, 0.006) 
Abbreviations: ACEi is angiotensin converting enzyme inhibitor; n/a is not applicable; RCT is randomized, controlled trial; SOLVD is 
Studies of Left Ventricular Dysfunction. 
a A RCT was chosen here to externally validate the CRAM methodology. In practice treatment will not be randomized in the target 
sample. 
Other footnotes: blanks indicate variable is not available for that study.   
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Table 3. Treatment Effect of Enalapril on Heart Failure Hospitalization or Death in the Target Sample (SOLVD Prevention Trial). 
Model 
True Effect Standardization, 
Covariate-basedb 
Standardization,  
Risk-basedc 
CRAM, 
 U-adjusted 
CRAM, 
 U Interaction-
adjusted 
Estimate t=1a -0.28 (0.10) -0.50 (0.22) -0.31 (0.13) -- -- 
1=-0.5  -- -- -0.43 (0.14)d -0.45 (0.15)e 
1=-1.0  -- -- -0.45 (0.16)f -0.43 (0.13)g 
 
Abbreviations: ATE is average treatment effect.  CRAM is calibrated, risk-adjusted modeling.   
Other footnotes: Numbers in parentheses are standard errors.   
a Marginal log hazard ratio, Equation 1  
bBased on boosted logistic regression. 
c Based on flexible logistic regression with a spline term for baseline risk. 
d The optimal * was 0.72.  
e The optimal * was 0.70.  
f The optimal * was 0.56.   
g The optimal * was 0.49 
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Table 4. Treatment Effect of Enalapril on Heart Failure Hospitalization or Death in a Distant Target Sample. 
Model 
True Effect Standardization, 
Covariate-basedb 
Standardization,  
Risk-basedc 
CRAM, 
 U-adjusted 
CRAM, 
 U Interaction-
adjusted 
Estimate t=1a -0.35 (0.19) -0.55 (0.43) -0.11 (0.19) -- -- 
1=-0.5   -- -- -0.31 (0.18)d -0.31 (0.19)e 
1=-1.0  -- -- -0.28 (0.18)f -0.33 (0.21)g 
 
Abbreviations: ATE is average treatment effect.  CRAM is calibrated, risk-adjusted modeling.   
Other footnotes: Numbers in parentheses are standard errors.   
a Marginal log hazard ratio, Equation 1  
b Based on boosted logistic regression. 
c Based on flexible logistic regression with a spline term for baseline risk. 
d The optimal * was 0.72.  
e The optimal * was 0.70.  
f The optimal * was 0.56.   
g The optimal * was 0.49.   
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Table 5. Treatment Effect of Enalapril on Heart Failure Hospitalization or Death in a Conventional Target Sample (Women Older than 
75 Years). 
Model 
Standardization, 
Covariate-basedb 
Standardization,  
Risk-basedc 
CRAM, 
 U-adjusted 
CRAM, 
 U Interaction-adjusted 
Estimate t=1a -0.094 (0.44) -0.64 (0.13) -- -- 
1=-0.5  -- -- -0.43 (0.08)d -0.41 (0.09)e 
1=-1.0 -- -- -0.44 (0.09)f -0.42 (0.08)g 
 
Abbreviations: ATE is average treatment effect.  CRAM is calibrated, risk-adjusted modeling.   
Other footnotes: Numbers in parentheses are standard errors.  True effect could not be computed in the validation trial due to small 
sample size of women older than 75 years. 
a Marginal log hazard ratio, Equation 1  
b Based on boosted logistic regression. 
c Based on flexible logistic regression with a spline term for baseline risk. 
d The optimal * was 0.72.  
e The optimal * was 0.70.  
fThe optimal * was 0.56.   
g The optimal * was 0.49.   
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Figure 1. Distribution of 1-yr Risk of Heart Failure Hospitalization or Mortality According to Study. 
 
Figure 1 Legend. 
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Abbreviations: SOLVD is Studies of Left Ventricular Dysfunction. SOLVD-P is the SOLVD Prevention Trial; SOLVD-R is the SOLVD 
Registry; SOLVD-T is the SOLVD Treatment Trial. 
Other footnotes: 1-yr risk of heart failure hospitalization or death is estimated with survival analysis as described in Methods.
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Figure 2. Cumulative Distributions of Standardization Weights for Standardizing the Trial and Bridging samples to the Distant Target 
Sample. 
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Figure 2 Legend: Green circles are weights for risk-based standardization of the bridging sample to the distant target sample; black 
circles are weights for risk-based standardization of trial sample to the distant target sample. 
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